01952 EVEREST MED-B
- 26.050
- +0.950+3.78%
EVEREST MED-B News
Genting Xinyao (01952) announced that the Macau Drug Administration of China approved the marketing license application for a new drug using itramod (VELSIPITY) for the treatment of moderate to severe active ulcerative colitis
Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, the Macau Special Administrative Region Drug Administration has officially approved the marketing license application for VELSIPITY (etrasimod) for the treatment of adult patients with moderate to severe active ulcerative colitis.
Express News | Genting Xinyao: Itramod's new drug marketing application approved in Macau
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Everest Medicines' Loss Widens in 2023
Everest Medicines' (HKG:1952) net loss attributable to equity holders widened to 844.5 million yuan in the year ended Dec. 31, 2023, from a loss of 247.3 million yuan a year ago, according to a Wednes
雲頂新耀-B：2023年度報告
Tencent recorded the biggest one-day increase in 10 months! The public offering group went south, and Zhang Kun and his team “overmatched” Hong Kong stocks
In the context of public fund giants collectively increasing their positions, Tencent Holdings recorded the biggest one-day increase in the last 10 months.
A quick look at the Hong Kong market | The three major indices have risen one after another. Technet stocks have generally risen, Tencent and Meituan have risen by more than 5%; Ideal has fallen by more than 8%
Many coal stocks fell sharply; Mongolian coking coal and China Coal Energy fell more than 6%; petroleum stocks fell, CNOOC Services fell more than 3%, and CNPC fell nearly 3%.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 8%, and many positive results of Nifukang appeared in WCN2024
Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
Hong Kong Stock Afternoon Review | The three major indices fell sharply, auto stocks fell, and Ideal Auto fell by more than 7%
Technology and network stocks generally fell; Xiaomi fell more than 4%, Meituan fell nearly 4%; shipping stocks rose higher, Pacific Shipping rose more than 9%, and COSCO Haineng rose more than 5%.
Hong Kong Stock Afternoon Review | The three major indices continued to weaken, the Tech Index fell nearly 3%, and Tech Net stocks and auto stocks generally fell
Biotech stocks fell collectively; Kingsley Biotech fell more than 4%; Genting Xinyao fell by more than 3%; gaming stocks fell, with Aobo Holdings and Sands China falling more than 4%; insurance stocks fell by more than 3%; and China Ping An fell nearly 2%.
Hong Kong Stock Afternoon Review | The three major indices declined, TechNet stocks and gold stocks fell, NetEase fell nearly 3%, and Zhaojin Mining fell nearly 9%
Biotech stocks fell, with Genting Xinyao falling more than 6%, and Kingsley Biotech falling nearly 5%; auto stocks fell by many stocks, Xiaopeng Motors fell nearly 4% and Geely fell nearly 3%; petroleum stocks improved, and CNPC rose more than 2%.
Changes in Hong Kong stocks | Genting Xinyao-B (01952.HK) rose more than 6% in the intraday period and surged more than 20% this week, the IgA nephropathy market reappeared with a 10-billion takeover
Genting Xinyao B (01952.HK) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
Express News | IgA nephropathy market reproduces a 10-billion acquisition case, and Genting Xinyao, the world's first therapeutic drug, Tolerant Fucang, is already on the market
Hong Kong Market Overview | The Hang Seng Index closed slightly higher. Power stocks and gold stocks were strong. Huaneng Power rose more than 11%
The trend of TechNet stocks was divided. Tencent fell more than 1% and NetEase rose 1%; auto stocks had mixed ups and downs, with Great Wall Motor up nearly 7% and Xiaopeng Motor falling nearly 3%; biotech stocks rose more than 11%; Genting Xinyao rose more than 11%, and Pharmaceutical Biotech rose more than 5%.
Genting Xinyao (01952.HK): Nifukang will soon start selling during the year, focus on the future volume of products
The 2023 performance is higher than our expectations. The company announced its 23-year results: revenue of 126 million yuan, sales revenue of the main products elacycline and nifukan; net profit to mother - 789 million yuan, with good control of three fees, 23 years
Hong Kong Stock Afternoon Review | The three major indices have risen one after another. The Tech Index has risen by nearly 4%, the Science Network stock and gold stock have risen together, Bilibili has risen more than 9%, and Lingbao Gold has risen nearl
Auto stocks rose more than 5%, and ideally nearly 5%; biotech stocks strengthened, Genting Xinyao rose more than 8%, and Pharmaceutical Biotech rose more than 7%; petroleum stocks rose more than 3%, CNOOC rose more than 2%, and Sinopec rose slightly.
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 5% after the performance, annual revenue increased nearly 9 times, and many executives announced a voluntary ban on sales
Genting Xinyao B (01952) rose more than 5% after the results. As of press release, it had risen 5.02% to HK$23, with a turnover of HK$58,3951 million.
Most Hong Kong pharmaceutical stocks strengthened, Genting Xinyao B rose nearly 5%
Gelonghui, March 28 | Genting Xinyao B rose 4.79%, Yao Ming Biotech rose 3.63%, Rongchang Biotech rose 2.92%, Pharmacom Combined rose 2.23%, and Viva Biotech rose 1.96%.
Analysis
Price Target
No Data
